190 related articles for article (PubMed ID: 38604812)
1. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
3. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
[TBL] [Abstract][Full Text] [Related]
7. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
9. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
11. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
12. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
13. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
15. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker.
White B; Patterson M; Karnwal S; Brooks CL
Proteins; 2022 May; 90(5):1210-1218. PubMed ID: 35037700
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
18. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
Front Immunol; 2021; 12():663379. PubMed ID: 33936101
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
